Argenta Discovery Articles
Galapagos in deal with Johnson & Johnson unit for oncology target in 33.5 million-euro deal; US FDA delays J&J’s tapentadol ER
5 October 2010
Showing 1-2 of 2 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
